Taspoglutide is a long-acting glucagon-like peptide 1 receptor agonist developed for treatment of type 2 diabetes. Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly, taspoglutide 20 mg weekly, or exenatide 10 µg twice daily. Though once weekly taspoglutide demonstrated greater glycemic control than twice-daily exenatide with comparable weight loss there were unacceptable levels of nausea/vomiting, injection-site reactions, and systemic allergic reactions with taspoglutide. Discontinuations were greater with taspoglutide. Antitaspoglutide antibodies were detected in 49% of patients. Roche has now made the decision to stop the development of taspoglutide and to return the product to the originator, Ipsen, which is currently pursuing further investigations.